Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies Article

sustainable development goals

publication date

  • February 1, 2022

webpage

published in

keywords

  • CRSwNP
  • ENT (rhinitis, sinusitis, nasal polyps)
  • clinical immunology
  • quality of life
  • responder analysis
  • rhinitis

start page

  • 244

end page

  • 249

volume

  • 52

issue

  • 2